Literature DB >> 6529533

Carbamazepine 10,11-epoxide in children.

G W Rylance, C Edwards, P R Gard.   

Abstract

Concentrations of carbamazepine (CBZ) and its 10,11-epoxide metabolite (CBZ-E) were measured in simultaneously collected plasma and mixed saliva samples from 15 children (aged 1-13 years). Saliva concentrations of CBZ and CBZ-E were measured in hourly samples taken from six of these children during dose intervals whilst on different dose or dose-frequency regimens. Saliva and plasma CBZ (r = 0.91; P less than 0.001) and CBZ-E (r = 0.91; P less than 0.001) concentrations were significantly correlated. The mean +/- s.d. steady state CBZ-E/CBZ concentration ratio in the six children was 0.40 +/- 0.21 and was similar at all times within the 12 h dose interval. The mean +/- s.d. percentage fluctuation of the combined CBZ + CBZ-E (103.0 +/-28.9) was significantly less than that of CBZ-E (145.5 +/- 52.8) but not CBZ (109.6 +/- 31.1). If CBZ and CBZ-E have equipotent anticonvulsant activity in man, the contribution of CBZ-E approximates to 30% of total anticonvulsant effect in children taking CBZ alone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6529533      PMCID: PMC1463678          DOI: 10.1111/j.1365-2125.1984.tb02566.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Saliva carbamazepine levels in children.

Authors:  G W Rylance; G M Butcher; T Moreland
Journal:  Br Med J       Date:  1977-12-03

2.  Simultaneous, rapid high-performance liquid chromatographic microanalysis of plasma carbamazepine and its 10,11-epoxide metabolite: applications to pharmacokinetic studies in humans.

Authors:  A Astier; M Maury; J Barbizet
Journal:  J Chromatogr       Date:  1979-10-11

3.  Kinetics of carbamazepine and its 10,11-epoxide metabolite in children.

Authors:  A Rane; B Höjer; J T Wilson
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

4.  Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients.

Authors:  J J MacKichan; P K Duffner; M E Cohen
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

5.  Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva.

Authors:  H G Westenberg; E van der Kleijn; T T Oei; R A de Zeeuw
Journal:  Clin Pharmacol Ther       Date:  1978-03       Impact factor: 6.875

6.  Carbamazepine and its 10,11-epoxide in children and adults with epilepsy.

Authors:  S Pynnönen; M Sillanpää; H Frey; E Iisalo
Journal:  Eur J Clin Pharmacol       Date:  1977-01-03       Impact factor: 2.953

7.  Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants.

Authors:  M J Brodie; G Forrest; W G Rapeport
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

8.  Carbamazepine dose-frequency requirement in children.

Authors:  G W Rylance; T A Moreland; G M Butcher
Journal:  Arch Dis Child       Date:  1979-06       Impact factor: 3.791

  8 in total
  2 in total

1.  Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children.

Authors:  R Hartley; W I Forsythe; B McLain; P C Ng; M D Lucock
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.